Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3

If approved, the oral GLP-1 would be Eli Lilly’s second marketed drug for obstructive sleep apnea after the GIP/GLP-1 injectable Zepbound secured the first approval in the space in December 2024.